BioHarvest Sciences Inc. Common Stock (BHST)
FairStock Score: 51/100 — MIXED
Key Financials
| Current Price | $1.72 |
| Market Cap | $100M |
| P/E Ratio | -3.37 |
| ROE | -142.5% |
| Dividend Yield | —% |
| Sector | Consumer Defensive |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a Graham-and-Buffett style investor, I look first for durable economics and a margin of safety. BioHarvest is a small, 89-employee consumer-defensive packaged-foods company with a botanical synthesis platform and two segments, Products and CDMO Services. It may have interesting technology, but I see no clear moat from the data: revenue is growing only modestly while profits are falling, and the latest reported quarter, fiscal Q2 2026, had revenue of $8.8 million, net income of -$3.7 million, and a margin of -42.04%. That is a cash-consuming business. Trailing free cash flow was -$10.8 million, and FairStock's FCF yield was -10.8% against a $99.7 million market cap. At the 2026-10-13 close of $1.82, FairStock's calculations show a negative P/E of -3.57, a P/B of 2.09, ROE of -142.50%, ROCE of -11.02%, and D/E of 0.79. The balance-sheet and distress signals are poor: Piotroski F-Score 3/9 and Altman Z-Score -0.76. The 52-week range of $1.37 to $12.65 shows how volatile the market's expectations have been. The Lynch category is none, because only 0 years of filed results are available and at least 3 are needed. I would require evidence of positive free cash flow, stable margins, and a durable competitive advantage before calling this cheap. Right now it is a speculative turnaround, not a value investment.
In plain English: BioHarvest Sciences is a small biotechnology company that makes plant-based health and wellness supplements and also sells development services. The business looks weak right now: it is losing money, burning cash, and has weak financial-strength scores. At $1.82, the price looks expensive relative to those losses, even though the shares are near the low end of their 52-week range.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer